The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: A population-based study

Cancer

Volumn 83, Issue 11, 1998, Pages 2335-2345

  Armes, Jane E ^a   Egan, A J Matthew ^a   Southey, Melissa C ^a,b   Dite, Gillian S ^b   McCredie, Margaret R E ^c,d   Giles, Graham G ^e   Hopper, John L ^b   Venter, Deon J ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CANCER RESEARCH DIVISION   (Australia)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e CANCER EPIDEMIOLOGY CENTRE   (Australia)

Author keywords

BRCA1; BRCA2; Early onset breast carcinoma; Genotype; Morphology; Phenotype correlation

Indexed keywords

ARTICLE; BREAST CARCINOMA; CANCER RISK; CANCER SUSCEPTIBILITY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; ONCOGENE; PRIORITY JOURNAL;

ADULT; AGE OF ONSET; APOPTOSIS; AUSTRALIA; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, TUMOR SUPPRESSOR; GERM-LINE MUTATION; HUMANS; NECROSIS; PHENOTYPE; POPULATION SURVEILLANCE;

EID: 0032400785     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N     Document Type: Article

References (47)

1. Jass JR, Smyrk TC, Stewart SM, Lane MR, Lanspa SJ, Lynch HT. Pathology of hereditary non-polyposis colorectal cancer. Anticancer Res 1994;14:1631-4.
2. Gibbs NM. Undifferentiated carcinoma of the large bowel. Histopathology 1977;1:77-84.
3. Schmidt L, Duh F-M, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
4. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations in BRCA1. N Engl J Med 1996;335:1413-6.
5. Jass JR. Familial cancer: histopathological perspectives. J Clin Pathol 1997;50:892-5.
6. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancer in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997;349:1505-10.
7. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, et al. Hereditary breast cancer: Pathobiology, prognosis and BRCA1 and BRCA2 gene linkage. Cancer 1996;77:697-709.
8. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996;56:471-74.
9. Marcus JN, Page DL, Watson P, Narod SA, Lenoir GM, Lynch HT, BRCA1 and BRCA2 hereditary breast carcinoma phenotypes. Cancer 1997;80:543-56.
10. Marcus JN, Watson P, Page DL, Narod SA, Tonin P, Lenoir GM, et al. BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat 1997;44:275-7.
11. Karp SE, Tonin SE, Begin LR, Martinez JJ, Zhang JC, Pollack MN, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 1997;80:435-41.
12. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90:1138-45.
13. Langsten AA, Malone KE, Thompson JD, Daling JR, Ostrander EA. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 1996;334: 186-8.
14. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
15. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King M-C. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1988;279:915-21.
16. Couch FJ, Weber BL, Breast Cancer Information Core. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Hum Mutat 1996;8:8-18.
17. The Breast Cancer Information Core Database. Available from URL: http://www.nhgri.nih.gov/intramural_research/ Lab_transfer/Bic/index.html [accessed February 2, 1998).
18. Cornells RS, Vasen HF, Meijers-Heijboer H, Ford D, van Vliet M, van Tilborg AA, et al. Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer. Hum Genet 1995;95:539-44.
19. Hopper JL. Some public health issues in the current state of genetic testing for breast cancer in Australia. Aust N Z J Public Health 1996;20:467-72.
20. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. New Engl J Med 1997;336:1409-15.
21. Whittemore AS, Gong G, Itnyre J. Prevalence of BRCA1 mutations and their contribution to breast and ovarian cancer: results from three US population-based case-control studies of ovarian cancer. Am J Hum Genet 1997;60:496-504.
22. Marcus JN, Watson P, Page DL, Lynch HT. Pathology and heredity of breast cancer in younger women. Monogr Natl Cancer Inst 1994;16:23-34.
23. Hopper JL, Giles GG, McCredie MRE, Boyle P. Background, rationale and protocol for a case-control-family study of breast cancer. The Breast 1994;3:79-86.
24. McCredie MRE, Dite G, Giles GG, Hopper JL. Breast cancer in Australian women under 40. Cancer Causes Control. 1998; 9:189-98.
25. Roest PA, Roberts RG, Sugino S, van Ommen GJ, den Dunnen JT. Protein truncation test (PTT) for rapid detection of translation-terminating mutations. Hum Mol Genet 1993;2: 1719-21.
26. Hogervorst FB, Cornelis RS, Bout M, van Vliet M, Oosterwijk JC, Olmer R, et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat Genet 1995;10:208-12.
27. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994;8:399-404.
28. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
29. Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 1994;8:392-8.
30. Page DL, Anderson TJ, Sakamoto G. Infiltrating carcinoma: major histological types. In: Page DL, Anderson TJ, editors. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone, 1987;193-235.
31. Ridolfi RL, Rosen PP, Port A, Kinne D, Mike V. Medullary carcinoma of the breast. A clinicopathologic study with 10 year follow-up. Cancer 1977;40:1365-85.
32. Elston CW. Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ, editors. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone, 1987;300-11.
33. Holland R, Peterse JL, Millis RR, Eusebi D, van de Vijver MJ, Zafrani B. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994;11:167-80.
34. Rosen PP, Oberman HA. Intraepithelial (preinvasive or in situ) carcinoma. In: Rosai J, Sobin LH, editors. Atlas of tumor pathology: tumors of the mammary gland. Fascicle 7. Washington: Armed Forces Institute of Pathology, 1993;119-56.
35. Gage I, Schnitt SJ, Nixon AJ, Silver B, Recht A, Troyan SL, et al. Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy. Cancer 1996;78:1921-8.
36. Sobol H, Stoppa-Lyonnet D, Bressac-de-Paillerets B, Peyrat JP, Kerangueven F, Janin N, et al. Truncation at conserved terminal regions of BRCA1 protein is associated with highly proliferating hereditary breast cancer. Cancer Res 1996;56: 3216-9.
37. Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, et al. Growth retardation and tumour inhibition by BRCA1. Nat Genet 1996;12:298-302.
38. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995;9:444-50.
39. WAF1/ciP1. Nature 1997;389:187-90.
40. Sun CC, Lenoir G, Lynch H, Narod SA. In-situ breast cancer and BRCA1. Lancet 1996;348:408.
41. Jacquemier J, Eisinger F, Guinebretiers J-M, Stoppa-Lyonnet D, Sobol H. Intraductal component and BRCA1-associated breast cancer. Lancet 1996;348:1098.
42. Jacquemier J, Seradour B, Hassoun J, Piana L. Special morphologic features of invasive mammary carcinomas in women under 40 years of age. Breast Dis Senol 1985;1:119-22.
43. Sigurdsson H, Agnarsson BA, Jonasson JG, Bjornsdottir IB, Barkardottir RB, Gudlaugsdottir S, et al. Worse survival among breast cancer patients in families carrying the BRCA2 susceptibility gene. Breast Cancer Res Treat 1996;37: 33.
44. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997;386: 804-10.
45. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997;88:265-75.
46. Porter DE, Dixon M, Smyth E, Steel CM. Breast cancer survival in BRCA1 carriers. Lancet 1993;341:184-5.
47. Porter DE, Cohen BB, Wallace MR, Smyth E, Chetty U, Dixon JM, et al. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutations in families linked to BRCA1 on chromosome 17q12-21. Br J Surg 1994; 81:1512-5.